Semaglutide and tirzepatide were approved for metabolic indications, but the research frontier extends to neurodegeneration, addiction, and cardiac protection. Historical articles may no longer reflect current regulatory status. Check the cited primary source.
Semaglutide and tirzepatide were approved for metabolic indications. The research frontier has since moved well beyond weight loss, with active clinical investigations in neurodegeneration, addiction, cardiac protection, and metabolic liver disease.
The reason GLP-1 receptor agonists have such broad research interest is anatomical: GLP-1 receptors are expressed not just in the pancreas and gut but throughout the central nervous system, the cardiovascular system, and peripheral tissues. When semaglutide binds GLP-1R in the hypothalamus, it modulates appetite. When it binds GLP-1R in the brain's reward circuits, it may modulate addictive behavior. When it acts in cardiomyocytes, it has direct cardioprotective effects.
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy
This distribution explains why a drug approved for type 2 diabetes is now being studied in Alzheimer's disease trials.
Neurodegeneration: A large Phase III trial (EVOKE) examined semaglutide in early Alzheimer's disease. Interim results from 2024-2025 showed mixed primary endpoints but significant secondary signals on cognitive decline markers.
Addiction: Multiple human studies have documented reduced alcohol consumption, smoking cessation, and drug craving in patients taking GLP-1 agonists. The mechanism appears to be modulation of mesolimbic dopamine circuits.
Cardiac protection: The SELECT trial (semaglutide, 17,604 patients) demonstrated a 20% relative risk reduction in major cardiovascular events in non-diabetic obese patients — independent of weight loss.
GLP-1 agonists have multiple human RCTs and confidence score 5/5 in the PeptideX index. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. The research frontier is expanding faster than the approved label. PeptideX tracks both.
Full GLP-1 compound profiles: peptidex.ai/compounds
*This content is for educational and informational purposes only. Not medical advice. See full Research Disclaimer.*
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy